Free Trial
NASDAQ:QDEL

QuidelOrtho Q1 2025 Earnings Report

QuidelOrtho logo
$28.09 +0.31 (+1.12%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$28.50 +0.41 (+1.46%)
As of 04/25/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QuidelOrtho EPS Results

Actual EPS
N/A
Consensus EPS
$0.61
Beat/Miss
N/A
One Year Ago EPS
N/A

QuidelOrtho Revenue Results

Actual Revenue
N/A
Expected Revenue
$694.97 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

QuidelOrtho Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

QuidelOrtho Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
J.P. Morgan Keeps Their Sell Rating on QuidelOrtho (QDEL)
See More QuidelOrtho Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like QuidelOrtho? Sign up for Earnings360's daily newsletter to receive timely earnings updates on QuidelOrtho and other key companies, straight to your email.

About QuidelOrtho

QuidelOrtho (NASDAQ:QDEL) provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

View QuidelOrtho Profile

More Earnings Resources from MarketBeat